secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2024-04-10T23:59:59+00:00
Accession:  0001193125-24-091463
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Interim Phase 2 data for AMX0035 shows clinically meaningful effects in Wolfram syndrome (n=8)
--------------------------------------------------------------------------------

- C-peptide AUC increased +15.6 ng*min/mL at Week 24; 7 of 8 participants had shorter time to peak C-peptide.
- HbA1c reduced by 0.26% on average; 6 of 8 improved; time in target glucose range improved by +7.1%.
- Visual acuity improved in 5 of 8 participants; one participant changed from legally blind to sighted.
- All 8 participants showed disease stability or improvement per CGIC and PGIC; no serious AEs related to AMX0035.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312524091463/0001193125-24-091463-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312524091463/d818999d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-091463

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer